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Pharmaceutical  development  and  manufacturing  process  optimization  work  was  undertaken  in  order
to propose  a  potential  paediatric  rectal  formulation  of  azithromycin  as  an  alternative  to existing  oral  or
injectable  formulations.  The  target  product  proﬁle  was  to be easy-to-use,  cheap  and  stable  in  tropical
conditions,  with  bioavailability  comparable  to  oral  forms,  rapidly  achieving  and  maintaining  bactericidal
concentrations.  PEG  solid  solution  suppositories  were  characterized  in  vitro  using  visual,  HPLC,  DSC,
FTIR  and  XRD  analyses.  In vitro  drug  release  and  in  vivo  bioavailability  were  assessed;  a study  in rabbits
compared  the  bioavailability  of  the  optimized  solid  solution  suppository  to  rectal  solution  and  intra-zithromycin
ntibiotic
ectal
uppository
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aediatric solid dispersion
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intra-venous  was  43%,  which  compared  well  to the  target  of  38%  (oral  product  in humans).  The results  of
3-month  preliminary  stability  and  feasibility  studies  were  consistent  with  industrial  production  scale-up.
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1. Introduction
Bacterial infections still take a heavy morbidity and mor-
tality toll on the lives of children, particularly those under 5
years of age (WHO, 2012). Against this scenario, there is a
lack of paediatric formulations of antibiotics that are adapted to
the needs of the developing world, where these infections are
mostly prevalent. Particularly needed are formulations that can
be administered by unqualiﬁed personnel to children who cannot
take oral medications (“non-per-os”) because their conditions are
deteriorating.
The desired target product proﬁle (TPP) was: (i) an antibiotic
with a spectrum of action covering the main agents causing pae-
Open access under CC BY license.diatric infections; (ii) use in both uncomplicated and complicated
cases (where oral administration is not possible (patient “non-per-
os”)); (iii) safe and easy to use by untrained personnel; amenable
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o near-home use; (iv) cheap; (v) stable in tropical conditions of
emperature and humidity.
Work conducted in our laboratory (Kauss et al., 2012) had inves-
igated options for a paediatric rectal formulation of azithromycin
AZ). The rectal route is acceptable in the targeted countries (Simba
t al., 2009; Thera et al., 2007), and can be used in both uncompli-
ated and complicated (“non-per-os” cases); there is evidence, for
nstance, that rectal artesunate can save lives in case of malaria
Gomes et al., 2009). AZ (a macrolide) was considered as a drug
andidate for this indication because of its broad antibacterial
pectrum of activity and pharmacokinetic properties (distribution
nd concentration in infected organs, prolonged half-life offer-
ng the convenience of once daily administration) (Jacobs et al.,
005; Langtry and Balfour, 1998; Van Bambeke and Tulkens, 2001).
mong existing chemical forms of AZ, the AZ dihydrate was  chosen
ecause of its stability (Gandhi et al., 2002).
There is no rectal formulation of a macrolide on the mar-
et, and little information exists on their rectal availability. The
eported rectal bioavailability would be acceptable for erythro-
ycin (28–54% bioavailability, varying with age (Stratchunsky
t al., 1991)) but very low for azithromycin (3.2% bioavailability
Bergogne-Bérézin and Bryskier, 1999)).
In order to improve AZ bioavailability (Kauss et al., 2012) we
ried: (i) enhancing viscosity and muco-adhesiveness to prolong
he residence time with rectal gels, (ii) dry form formulated as rectal
apsule, and (iii) enhancing solubility with solid dispersion sup-
ositories. Fatty-base suppositories were excluded because their
ow melting point makes them incompatible with tropical condi-
ions. The most promising prototype was the suspended AZ PEG
uppositories based on solid dispersion approach, which attained
8% bioavailability (Kauss et al., 2012). In a solid dispersion, active
ngredients are dispersed in an inert carrier or matrix of solid state,
repared by melting, solvent or melting-solvent method (Chiou
nd Riegelman, 1971). Solid dispersions include eutectic mixtures,
olid solutions, glass solutions and suspensions, amorphous pre-
ipitations, compound or complex formation, combinations and
iscellaneous mechanisms (Chiou and Riegelman, 1971).
The aim of the current study was to optimize the AZ suppository
ormulation in order to enhance its rectal bioavailability and render
t amenable to further development.
. Materials and methods
.1. Materials
Azithromycin dihydrate (AZ) was generously donated by Pﬁzer
France). Zithromax® (Pﬁzer, USA) was used as IV AZ formulation.
Pharmaceutical excipients, namely polyethylene glycol (PEG)
500 and 4000 purchased from Fagron (Spain) and Miglyol 812N
Inresa, France) were of pharmaceutical grade. All other chemicals
nd solvents were of analytical reagent grade. Water was puriﬁed
nd deionized by the Millipore® Simplicity system (USA).
.2. Suppository preparation
All the tested formulations except IV (Zithromax®, Pﬁzer) were
eveloped in our laboratory.
All suppositories were prepared using the moulding method.
To obtain suspended AZ suppositories, PEGs were melted at
5 ◦C in a water bath and then AZ was dispersed under mechanical
tirring at 150 rpm.
For co-melted AZ suppositories, PEGs were pre-melted at high
emperature above the melting points of all constituents (130 ◦C)
n an oven (Jouan Paris, France) and then AZ was added. Thearmaceutics 441 (2013) 218– 226 219
preparation was  left in the oven until AZ was  melted and stirred
to obtain a homogeneous blend.
Finally, in the case of solid solution AZ suppositories, PEGs were
melted at 90 ◦C in a water bath and AZ was added. The mixture was
stirred until obtaining a homogenous limpid blend.
For all suppositories, the blend was cooled to a temperature of
55–60 ◦C before being poured in 2 g suppository moulds. They were
allowed to harden at room temperature in a dessicator for at least
24 h and stored in individual alu/alu blister or kept in their plastic
moulds in a fridge before further analysis or use.
While screening different options for the feasibility of solid
solution suppositories, the AZ content was  varied and changes com-
pensated with the PEG mixture content (qsf 100%, while keeping
the ratio PEG 1500/PEG 4000 constant). For manufacturing opti-
mization, the manufacturing process was  varied while keeping
the formulation unchanged. For scale-up studies, batch quantities
were increased while the process and the formulation remained
the same.
2.3. In vitro pharmacotechnical controls of AZ PEG suppositories
Suppositories were visually evaluated at each withdrawal and in
each storage condition; the colour, the limpidity and consistency
were taken into account. The melted aspect of suppositories was
also observed on a watch glass. For this purpose, crushed supposi-
tory aliquot of approximately 50 mg  was  melted at 70 ◦C in an oven
(Jouan-Paris, France) on the watch glass.
Dissolution behaviour of AZ suppositories (n = 6 for each for-
mulation and each storage condition) was compared using the
Pharmacopoean II apparatus (SOTAX AT 7, Switzerland). Suppos-
itories were introduced in bowls containing 250 ml  of phosphate
buffer (50 mM)  pH 7.0 maintained at 37.0 ◦C ± 0.2 and 75 rpm. Sam-
ples (1 ml  aliquot replaced by an equal volume of fresh dissolution
medium) were withdrawn at time 0, 15, 30, 45, 60, 90 and 120 min
using a 10 m porous preﬁlter. Samples were diluted suitably using
phosphate buffer before HPLC analysis.
AZ drug content was determined using HPLC method described
beneath. A 65 mg  of crushed suppository was dissolved in 20 ml
with HPLC mobile phase. After 10 min  of magnetical stirring, the
ﬁltered preparation was  analyzed without further dilution.
2.4. HPLC analysis of azithromycin
AZ content and dissolution proﬁle were determined by an
HPLC system composed of 515 HPLC Pump Waters, Waters 2487
Dual  Absorbance Detector and Waters 717 plus Autosampler
(Waters, France). Data were managed using Millenium32 Chro-
matography manager (Waters, France). HPLC method was based
on Gaudin et al. (2011) method. AZ was  eluted using Luna C8
EC 5 m,  150 mm  × 4.6 mm column (Phenomenex, France) ther-
mostated with Crococil oven (CIL, Saint Foy la Grande, France)
at 45 ◦C. The mobile phase at apparent pH of 9 was composed
by methanol/phosphate buffer 15 mM (80/20, v/v) at ﬂow rate of
1.2 ml  min−1. The injected volume was 10 l and AZ was detected
at 215 nm.
2.5. Differential scanning calorimetry (DSC) analysis
DSC analysis was performed using a differential scanning
calorimeter (Mettler Toledo TA controller and DSC30, Switzerland)
with STARe software. DSC method consisted in a heating rate of
5 ◦C min−1 in the range of 30–180 ◦C for thermograms, or 2 ◦C min−1in the range of 30–150 ◦C for melting point determination (n = 3 for
each formulation). Precisely weighted samples of 6–8 mg  were in
aluminium pans, sealed and perforated with a pin. An empty sealed
perforated aluminium pan was used as reference. For comparison,
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heoretical melting points were calculated as a mean of individual
elting points taking into account the relative content.
.6. Crystallographic studies
Powder X-ray diffraction patterns for AZ, physical mixture, PEG
500 and 4000, and AZ suppositories were acquired using a X-
ay diffractometer (AXS D5005, Bruker, Germany). Powder samples
ere placed on a stainless steel support and exposed to Cu K radi-
tion ( = 1.54056 A˚) in the range of 3◦ < 2 < 40◦ in continuous scan
ode using a step size of 0.02◦, 2 and a step time of 20 s. A gener-
tor tension of 30 kV and of 40 kV and current of 30 mA  was used
or the XRD analysis of AZ suppositories.
.7. Infrared analysis
Spectra of AZ, PEG 1500 and 4000 and suppositories were ana-
yzed by Fourier transformed infrared (FTIR), using Mattson model
enesis II FTIR spectrometer controlled by Winﬁrst software from
attson instruments Inc. (Winlab. Instruments, Bagnolet, France).
amples were ground and mixed with potassium bromide at 1%
eight ratio and then compressed at a pressure of 8 tonnes during
 min  (hydraulic press). Single beam spectra were recorded after
veraging 20 scans at a resolution of 0.5 cm−1, between 4000 and
00 cm−1 and corrected against the background spectrum of the
tmosphere. All spectra were obtained in the absorbance mode and
hen converted in transmittance. Calibration of the instrument was
epeated periodically during operation.
.8. Preliminary stability study
A preliminary stability study was realized on solid solution AZ
uppository batch during three months. One part of the batch kept
n individual alu/alu blister or plastic mould in a climatic chamber
Froilabo/Frilabo, France) was used for an accelerated degradation
tudy (40 ◦C and 75% relative humidity) and the other one for an
mbient condition stability study.
.9. Animal pharmacokinetic experimentation
Animal experiments were performed at Etablissement Franc¸ ais
u Sang (Aquitaine-Limousin, Bordeaux, France; accreditation
umber for animal experimentation no. A33063080).
Five adult healthy New-Zealand white rabbits, provided by
Le grand Claud” (Eyvirat, Dordogne, France), were used for the
harmacokinetic study of each form. Animals were placed into
ndividual cages in controlled temperature (18–21 ◦C) and humid-
ty (40–70%) room. They were fastened for 24 h prior and during
he experimentation but allowed free access to water and glucose
olution (5%).
All forms for in vivo evaluation in rabbits were prepared extem-
oraneously. Rectal formulation mass equivalent to 20 mg/kg was
djusted individually to each animal body weight. Solid solution
uppositories were prepared as described in Section 2.2.  Results
rom previously published work were used for suspended AZ sup-
ository (Kauss et al., 2012, formulation D) for comparison. The
ectal oily suspension was prepared by dispersion of AZ (sieved
t < 250 m)  in medium chain triglyceride oil (Miglyol 812N) and
erved as rectal reference for PK studies. AZ IV solution used was
he one commercially available (Zithromax®, Pﬁzer). An IV dose of
0 mg/kg was administered to animals.
The insertion into the animal’s rectum was performed using 1 ml
yringe for liquid formulations and 1 ml  pipette like device with
arge aperture and piston for dry forms.
Blood samples (at least 1 ml  of blood per time point) were
ollected into heparinized plastic tubes by inserting a 22 GA I.V.harmaceutics 441 (2013) 218– 226
catheters (BD Insyte®, Spain) in peripheral ear vessels (opposite
ear was  used for IV administration). They were collected at pre-
dose, then 12 samples in 48 h post-administration and kept on
crushed ice before centrifugation at 1200 × g during 10 min  within
30 min  after collection. Only supernatants (at least 500 l) were
transferred into cryo tubes and conserved at −80 ◦C prior analysis.
The maximal concentration (Cmax), and the time to reach the
maximal concentration (Tmax) of each formulation were taken
directly from mean plasma concentration–time proﬁle curves,
whereas the area under the concentration–time curve (AUC) was
calculated using trapezoidal rule. Standard deviations are given
for all PK parameters. Absolute and relative bioavailability were
estimated from mean AUC0–24 h and AUC0–48 h. Data for 24 h were
analyzed by comparison with previously obtained parameters for
suspended AZ suppositories (Kauss et al., 2012).
2.10. Sample preparation and LC–MS/MS conditions for PK
samples
Plasma samples underwent a solid-phase extraction (Oasis HLB,
Waters, USA) before analysis by a LC–MS/MS system composed of
a Hitachi LaChrom Elite LC (Hitachi, Japan) with an Esquier 4000
mass spectrometer equipped with an electrospray interface. Mul-
tiple reaction monitoring (MRM)  was used during AZ quantiﬁcation
based on transitions m/z 749–591 and 753–595 for AZ and stable
labelled AZ, respectively.
The separation was  carried out on a Hypersil Gold CN
150 mm  × 2.1 mm I.D column (Thermo Scientiﬁc, USA) using a
mobile phase of acetonitrile–ammonium acetate 50 mM (70/30%,
v/v) at a ﬂowrate of 0.3 ml  min−1. The method has been vali-
dated according to US FDA guidelines over two calibration ranges
15–720 ng ml−1 and 1.5–72 ng ml−1.
2.11. Statistical analysis of data
Drug dissolution proﬁles were analyzed using the difference fac-
tor (f1) and similarity factor (f2) as described by Moore and Flanner
(1996) and the FDA (1997).  Two  dissolution proﬁles were consid-
ered similar if f1 values were up to 15 and f2 values were greater
than 50 (Palanisamy and Khanam, 2011; Chevalier et al., 2009).
In vitro and in vivo data were analyzed using Student bilateral
“t” test. The difference was considered signiﬁcant for p < 0.05.
3. Results and discussion
3.1. Development and optimization of AZ suppositories
AZ is a class IV/II BCS drug (WHO, 2005), i.e. exhibiting poor
aqueous solubility and/or poor permeability. It remains unclear
whether poor bioavailability is due to poor solubility alone, or
also poor permeability contributes (WHO, 2005). Solid dispersions,
solutions or eutectic mixtures are commonly used to improve the
rectal absorption of poorly soluble drugs (Iqbal et al., 2011; Leuner
and Dressman, 2000) by enhancing their solubility and dissolution
rate (Craig, 2002; Jigar et al., 2011; Kalia and Poddar, 2011), and are
compatible with our TPP.
Through previous work in our laboratory, suspended AZ PEG
suppositories provided the highest rectal Cmax and AUC0–24 h in
rabbits (Kauss et al., 2012) and were selected for further improve-
ment. The bioavailability of AZ suspended suppositories was ∼28%
relative to IV Zithromax® – an encouraging result considering the
reported 38% oral bioavailability of Zithromax® capsules in humans
(Pﬁzer, 2012). PEGs as hydrophilic base for suppositories present
various advantages such as low toxicity, high water solubility and
low cost (Parmar et al., 2011), which complied with our TPP. As
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40
44
48
52
56
60
0 10 20 30 40 50 60
T
e
m
p
e
ra
tu
re
 (
C
)
PEG 4000 cont ent in  PEG  mi xture ( %)
DCS
Theoreti cal mel ting po int
Fig. 1. Comparison of theoretical and DSC (differential scanning calorimetry) mea-
sured melting point of various mixtures of suppository excipients (PEG 1500 and
4
i
r
P
s
e
t
t
r
4
T
t
2
m
c
d
w
o
a
s
t
m
a
s
f
t
l
a
p
b
c
h
1
c
p
c
d
T
F000, expressed as % of PEG 4000 in PEG 4000/1500 mixture). Theoretical melt-
ng  point was calculated from individual melting points of PEG 1500 and PEG 4000
especting their relative proportions.
EGs might be slightly irritant in children (EMA, 2006), no other
urfactants were added to avoid problems with local tolerability or
arly expulsion of the form. A mixture of two PEGs, one of low and
he other of high molecular weight, is commonly used for conven-
ional rapid-release suppositories (Saleem et al., 2008). Different
atios of PEG 1500/4000 were tested; 80% PEG 1500 plus 20% PEG
000 (melting point >50 ◦C as per the TPP) was  selected (Fig. 1).
hese results are in line with previous data on PEG, showing that
he melting point increases with its molecular weight (Taha et al.,
003; Vippagunta et al., 2007).
AZ could not be dissolved in given proportions in melted PEG
ixture at 70 ◦C. Using ethanol 95% as an intermediate solvent
aused AZ to precipitate as soon as ethanol started to evaporate; AZ
issolution in PEG of lower molecular weight (PEG 200, PEG 400)
as still incomplete in given proportions after 48 h stirring. The aim
f the optimization of AZ suspended suppositories was to obtain
 homogenous formulation to accelerate drug release and avoid
edimentation occurring with suspensions. Alternative options
o suspended suppositories were: (i) co-melted suppository, as
elted AZ (123 ◦C) and melted PEG mixture (51 ◦C) were miscible
nd (ii) solid solution suppository. Suspended, co-melted and solid
olution suppositories were prepared with the same quantitative
ormulation, but through various preparation processes, which lead
o different ﬁnal forms. Table 1 provides information on the formu-
ation of all suppositories and Table 2 on the manufacturing process
nd characterization.
Suspended AZ suppositories had the advantage of being pre-
ared at low temperature (65 ◦C) in a water bath (hence simplicity),
ut lacked homogeneity and drug release was delayed.
A second option was  to mix  AZ and PEGs once melted to form
o-melted suppositories. However, as the melting point of AZ is
igh (123 ◦C), it required the process temperature to be above
25 ◦C (Table 2), requiring an oven or an oily bath, instead of
ommonly used water bath. When kept at high temperature over a
rolonged period of time, the preparation became cloudy and the
olour changed to orange, which was a sign of a degradation of the
rug, conﬁrmed by HPLC analysis. Moreover, stability problems
able 1
ormulation of AZ suppository.
Content Weight (mg) Proportion (% w/w)
AZ (equivalent AZ anhydrous) 419 (400) 16.1 (15.4)
PEG 1500 1760 67.7
PEG 4000 440 16.9armaceutics 441 (2013) 218– 226 221
have been described for PEGs when manufactured by hot melted
method, due to a reduction of PEG chain length (Leuner and
Dressman, 2000). Therefore this option was  not pursued.
The remaining option was to prepare AZ solid solution sup-
positories. Solid solutions reportedly increase drug solubility and
release (Craig, 2002; Jigar et al., 2011; Kalia and Poddar, 2011)
and are simple to manufacture. The optimal process tempera-
ture to prepare AZ solid solution suppositories was 80 ◦C, which
represented the best compromise between process time and tem-
perature (the higher the temperature, the shorter the time, but the
higher the risks of product degradation). Pre-melting PEGs mixture
(2 min  at 90 ◦C) before introducing AZ did not inﬂuence the process
time and avoided the additional co-grinding step.
3.2. In vitro characterization of AZ PEG suppositories
Table 2 summarizes the results of in vitro characterization of the
three types of AZ suppositories, suspended, co-melted and solid
solution suppositories. The aim of this evaluation was  to compare
drug release for solid solution suppositories to the other types.
The retention time of AZ by HPLC was 5.7 min. AZ content was
within 100 ± 5% drug content for all formulations. Drug released
after 45 min  was  faster for solid solution than suspended sup-
positories (p < 0.01) and statistically not different from co-melted
suppositories.
By visual inspection, solid solution AZ suppositories were white,
translucent and marbled (same aspect as blank suppositories with-
out AZ), compared to suspended suppositories which were cloudy.
When melted, solid solution AZ suppositories were crystal clear the
different components are miscible at liquid state, as reported for
solid solutions and eutectic mixtures (Leuner and Dressman, 2000).
Comparatively, AZ particles in suspension were clearly visible in the
suspended AZ suppositories.
DSC was  used to determine different melting points and possi-
ble interactions between constituents. AZ has a broad melting point
peak on DSC thermogram which has been ascribed to the departure
of crystalline water simultaneously when melting. Resulting prod-
ucts described are AZ monohydrate and anhydrous azithromycin,
reportedly less stable than the dihydrate (Gandhi et al., 2002).
DSC thermograms of AZ and PEG 1500/4000 mixture exhibited
endothermic melting points at 123.3 ◦C and 50.7 ◦C, respectively.
On suppository thermograms, the AZ melting peak did not appear.
AZ and PEG behaved as a single entity, with one melting point
around 51 ◦C. AZ was  not completely soluble in melted PEG at
15.4% (w/w) and precipitated when included in melted PEG as
ethanolic solution. A simple dissolution of AZ in PEG could there-
fore not explain the obtained homogenous preparation. Its lower
melting point and rapid drug release of solid solution supposito-
ries favoured a eutectic mixture (Vippagunta et al., 2007), though,
the difference in melting points was  too narrow to exclude a peri-
tectic system (Sadoway, 2004). The reason for the absence of the
endothermic peak of AZ could be that the drug would dissolve and
distribute within the melted carrier and convert from crystalline
to amorphous form (Damian et al., 2000; Guyot et al., 1995; Khan
et al., 2011; Parmar et al., 2011). This conversion is thought to be
the reason of the increased solubility and accelerated drug release
in eutectic systems and solid solutions (Craig, 2002; Jigar et al.,
2011; Kalia and Poddar, 2011) and is conﬁrmed by our drug release
results. Furthermore, among the existing methods for solid solution
preparation, the fusion method chosen appears to enhance this con-
version over solvent method (Jigar et al., 2011). X-ray diffraction
performed on solid solution suppositories conﬁrmed the conver-
sion of AZ from crystalline to amorphous form (Fig. 2). The analysis
of atomic positions of AZ in its crystalline structure (Fig. 3) showed
that both molecules of water were engaged in the spatial arrange-
ment of AZ, and thus are very important for its crystalline pattern.
222 T. Kauss et al. / International Journal of Pharmaceutics 441 (2013) 218– 226
Table 2
Preparation and in vitro characterization of AZ PEG suppository formulations.
Formulation/suppository Suspended Co-melted Solid solution
Preparation
Process temperature (◦C) 65 130 90
Equipment Water bath Oven Water bath (PEG pre-melted)
Process time (min) 64 42 17
In  vitro characterization
Suppository aspect Whitish cloudy White translucent marbled White translucent marbled
Melting point 51.1 50 52.2
Melted aspect Suspension Cloudy Crystal clear
Mass
Mean ± SD (g) 2.56 ± 0.003 2.67 ± 0.064 2.62 ± 0.015
Uniformity ± 5% Yes Yes Yes
Drug  content (% of theoretical) 98.3 ± 0.9 97.4 ± 0.6 99.9 ± 0.3
Drug  release at 45 min  (%) 73.8 ± 1.8* 74.3 ± 2.1 77.3 ± 2.4*
X ray diffraction AZ crystalline ND AZ amorphous
FTIR  analysis No interaction AZ-PEG
Hydrogen bond AZ-H2O
ND Interaction AZ-PEG (red shift)
Hydrogen bond AZ-H2O disrupted (blue shift)
Key: ND: not determined.
* p = 0.0013 between suspended and solid solution 45 min  drug release (t test).
F ent AZ
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fig. 2. X-ray diffraction patterns of AZ, excipients, physical mixture and the differ
nd  suspended suppositoryes, disappears in solid solution suppositories. Key: (a) th
uppository, and (f) solid solution AZ suppository.
ur ﬁndings are consistent with previous reports (Djokic et al.,
988; Gandhi et al., 2002) and with the results of FTIR analy-
is. Differently from suspended suppository and pure AZ spectra,
roader FTIR bands were observed for solid solution suppository,
uggesting interactions between components (Fig. 4). In view of
he molecular conformation of AZ and the chemical structure of
EG, hydrogen bonds between the free O H of the components
ere expected for solid solutions. Indeed, the spectrum presented
 red shifting of the O H stretching (3495.60 and 3560.68 cm−1
owards 3429.31 cm−1) and a blue shifting of the C O stretching
1720.63 towards 1730.56 cm−1) associated with decreased peak
ntensity (Fig. 4). These results indicated that one hydrogen bond
ormed between the free O H of the AZ and PEG (red shifting) while
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ig. 3. Graphical representation of AZ dihydrate molecular interaction: hydrogen
onds between 2 molecules of crystalline water and polar groups of AZ are impor-
ant for AZ·2H2O spatial arrangement and interfere while solid solution with PEG is
ormed. suppository formulations: crystalline structure of AZ, visible in physical mixture
ical AZ, (b) experimental AZ, (c) excipients, (d) physical mixture, (e) suspended AZ
the second hydrogen bond between a water molecule and AZ was
disrupted (blue shifting). These results are consistent with previ-
ous data (Ansari et al., 2010) and supported the results of X-ray
diffraction.
In conclusion, the in vitro characterization indicated that AZ
solid solution suppositories gave the fastest drug release and guar-
anteed optimal physical stability of the formulation (absence of
sedimentation), although the exact nature of the solid solution
(eutectic or peritectic) remained unclear. This formulation was fur-
ther evaluated for stability and in vivo bioavailability.
3.3. Preliminary stability study of AZ solid solution suppositories
Stability is expected to be a limiting factor in the develop-
ment of solid dispersions (Tajarobi et al., 2011); the pre-stability
study of solid solution suppositories was performed before animal
experimentation. For each storage condition, namely at ambient
temperature/humidity and under accelerated ageing conditions
(40 ◦C/75%RH), two primary conditions, i.e. plastic mould or indi-
vidual alu/alu blister were tested. Samples were taken at time 0, 2,
5, 8 and 12 weeks to characterize aspect, drug content, in vitro drug
release and melting point.
No signiﬁcant change of appearance (solid or melted), melt-
ing point or AZ content (100 ± 5%) was  noticed during 12-week
study for solid solution AZ suppositories in alu/alu blisters (Table 3).
For those kept in plastic mould at 40 ◦C/75%RH, the suppository
tail became progressively pastier in few weeks, probably due to
water capture. Presence of PEG 1500 in high content is known
to make preparations particularly hygroscopic (Price, 2003). The
aspect change was  paralleled by a decrease in the melting point
and a visible peak of water evaporation on the DSC thermogram.
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Pig. 4. FTIR (Fourier transform infrared spectroscopy) spectra of AZ and blank or AZ
olution AZ suppository, and (d) blank (PEG 1500 and 4000) suppository.
ecreased drug content (35% and 7% degradation for suppository
ail and head, respectively) was found for AZ plastic mould suppos-
tories after 12 weeks, but not when packaged in alu/alu blisters
Table 3).
The dissolution proﬁles of AZ suppositories immediately follow-
ng their preparation and after 12 weeks were compared using the
DA-deﬁned difference factor f1 and similarity factor f2 (Chevalier
t al., 2009; FDA, 1997; Palanisamy and Khanam, 2011). Results
howed that proﬁles were similar for suppositories from ambi-
nt and accelerated ageing conditions when stored in alu/alu
listers, but borderline for similarity (f1 = 14.88) for those stored
n plastic moulds in accelerated ageing conditions. Drug release
fter 45 min  was signiﬁcantly modiﬁed after 12 weeks (ambient
r 40 ◦C/75%RH) for suppositories kept in plastic moulds (t-test,
 < 0.05), while it remained unchanged when kept in alu/alu blis-
ers.
able 3
reliminary stability studies of solid solution AZ suppositories.
T0 T + 12 weeks
Ambient condition 
Plastic mould 
Aspect
Solid aspect White/translucent
marbled
White/translucent
marbled
Melted aspect Crystal clear Crystal clear 
Melting point (◦C) 52.2 53.3 
Drug content (% of theoretical) 99.9 ± 0.3 101.8 ± 1.9 
Drug  release at 45 min  (%) 77.3 ± 2.4 71.8 ± 2.9*
* p < 0.05 (t test).ining suppository formulations. Key: (a) suspended AZ suppository, (b) AZ, (c) solid
In conclusion, the preliminary stability study highlighted (i) the
good stability of AZ solid solution suppository when kept in alu/alu
blister and (ii) the need to protect the suppositories from humidity.
3.4. In vivo bioavailability study of AZ solid solution suppositories
The plasma proﬁles obtained in rabbits with AZ solid solution
suppositories were compared to rectal suspension used as rec-
tal control (both administered at 20 mg/kg of body weight) and
to IV injection (Zithromax®) at 10 mg/kg. Doses were determined
according to previously published animal pharmacokinetic data
(Shepard and Falkner, 1990).The main disposition parameters of AZ are summarized in
Table 4 and Fig. 5. Compared to rectal suspension, solid solu-
tion AZ suppositories gave an increased Cmax, AUC0–24 h and
Tmax. The estimation of the bioavailability of solid solution AZ
40 ◦C/75%RH
Blister Plastic mould Blister
White/translucent
marbled
Head:
white/translucent/marbled
Tail: pasty/white
White/translucent
marbled
Crystal clear Crystal clear Crystal clear
53.3 Head: 50.0
Tail: 46.3
55.5
97.9 ± 0.3 Head: 92.9 ± 2.8
Tail: 64.4 ± 12.0
99.9 ± 0.7
78.2 ± 2.8 69.1 ± 6.7* 75.1 ± 12.3
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Table 4
Pharmacokinetic parameters and comparison of AZ PEG suppositories in rabbits (mean ± S.D.).
Formulation/PK parameters IV Rectal suspension Solid solution suppository Solid solution/suspended
suppositorya ratio
Cmax (ng ml−1) 2572 ± 1277 185.5 ± 57 1656 ± 334 6.4
Tmax (h) – 0.183 ± 0.082 0.300 ± 0.100 0.2
AUC0–24 h (ng × h/ml) 2912 ± 911 859 ± 198 2697 ± 819 1.9
Estimated absolute bioavailability 24 h (%) 100 14.7 46.3 1.6
Estimated relative bioavailability 24 h (%) – 100 314.2 1.4
AUC0-48h (ng ×h/ml) 3882 ± 1188 1258 ± 438 3333 ± 1139 ND
Estimated absolute bioavailability 48 h (%) 100 16.2 42.9 ND
Estimated relative bioavailability 48 h (%) – 100 265 ND
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a Suspended AZ PEG suppository published by Kauss et al. (2012) (data determin
uppositories relative to IV was 43% after 48 h (which met  our
arget of 38% – the bioavailability obtained with the oral for-
ulation in humans). Compared to our previous results (Kauss
t al., 2012) the rectal and IV references were not statistically
ifferent (p > 0.05), while the AUC0–24 h increased for the newly
ormulated solid solution suppository compared to suspended
uppository (2697 ng h/ml and 1400 ng h/ml, respectively). The
stimation of relative bioavailability against the rectal reference
AUC0–24 h suppository/AUC0–24 h rectal suspension) was 314% and 232%
or solid solution and suspended suppository, respectively. Addi-
ionally, Tmax was faster for solid solution compared to suspended
uppositories (0.3 h and 1.7 h, respectively) and Cmax was  6 times
igher (Fig. 5 and Table 4).
Macrolides are widely distributed in the body, with signiﬁcant
issue accumulation; they are fat-soluble, basic molecules, which
akes them to diffuse easily through biological membranes and
ccumulate within acidic cellular compartments. These properties
ould explain the rapid decrease of plasma concentrations during
he distribution phase both for IV and solid solution AZ suppository
orms (Fig. 5).
In summary, the AZ PEG solid solution suppository shows an
mproved pharmacokinetic proﬁle, namely better bioavailability
higher Cmax and shorter Tmax, which are important for an emer-
ency paediatric treatment), and higher exposure (AUC).
Taking into account the small number (n = 5, ethical reasons)
f experimental animals, these results are indicative. There was
o visible sign of local intolerance. The standard battery of toxico-
ogy and toxicokinetic studies will be required if this drug is to be
eveloped further.
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3.5. Feasibility of solid solution AZ PEG suppositories in view of
industrial production scale-up
The feasibility of scaling-up the production of these AZ PEG
suppositories was  studied. PEG pre-melting time and AZ-PEG
homogenous mixture formation were modelled (see Fig. 6). Linear
and logarithmic trend curves with determination coefﬁcients (R2)
were ﬁtted to the experimentally obtained results. For the calcula-
tion of the time necessary for pre-melting, the best extrapolation
was  obtained by linear regression for PEGs and by, logarithmic
regression for homogenous AZ PEG mixture.
Product stability formulated under manufacturing conditions
(water bath at 90 ◦C) was determined at 4.5 h: no signiﬁcant change
in AZ HPLC impurity proﬁle was noted; a slight decrease in AZ con-
tent (AZ content in 97–106% range from T0.5 h to T3.5 h, but 93%
of theoretical content at 4.5 h) concomitant with a slight precipita-
tion occurring between 3.5 and 4.5 h. The process should therefore
not exceed 3.5 h in a water bath at 90 ◦C without further stability
studies.
AZ content had been ﬁxed to 400 mg  anhydrous AZ, repre-
senting 15.4% (w/w) content in suppository formulation (Kauss
et al., 2012). In view of future paediatric use, different AZ contents
(104–780 mg/suppository) were explored. The formulations con-
taining 104–702 mg  of AZ per suppository (i.e. 4.0%, w/w  to 27.0%,
w/w)  gave solid solutions, but precipitation occurred for the drug
content higher than 27% (w/w).
The optimized solid solution suppositories provided enhanced
rectal bioavailability. With AZ becoming amorphous, drug release
was  faster and the manufacturing process of homogenous blend
easier compared to a suspension. The feasibility of solid solution
was  only possible under certain conditions (temperature > 80 ◦C
in the presence of PEG), as AZ at deﬁned dose was not soluble
in melted PEG at 60 ◦C. The hygroscopic properties of PEG could
y =  11. 25ln (x) - 16.03
R² = 0.9 86
y = 0 .047x + 1 .284
R² = 0.998
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Fig. 6. Scale-up modelling for increasing quantity of AZ PEG solid solution sup-
positories prepared in water bath at 90 ◦C. Time necessary to obtain homogenous
(melted for blank PEG or solid solution for AZ containing) formulation was  assessed
as  a function of the quantity of formulation (size of batch).
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xplain why the dehydration, which usually occurs above 100 ◦C
Gandhi et al., 2002), took place at lower temperatures producing
onohydrate or anhydrous azithromycin with enhanced solubility
n melted PEGs.
. Conclusion
Solid solution AZ suppositories are a candidate product for fur-
her development. Optimization work has made the product meet
riteria for release, bioavailability, stability and industrial produc-
ion scale-up. While results must be conﬁrmed in humans, the
elative bioavailability in the rabbit of this product (43%) was
omparable to that of the oral formulation in humans (38%). This
ormulation (melting point above 50 ◦C) can withstand tropical
lime (zone IV).
We reckon that this product will have both utility and a poten-
ial market. It could complement the oral form for uncomplicated
nfections and the injectable form for severe infections, but also ﬁll
 gap in conditions were oral cannot be taken and injectable is not
vailable or cannot be administered safely. It is easy to administer
y unqualiﬁed personnel and would be eligible to near-home use.
Furthermore, in addition to its antibacterial effects, AZ possesses
ntimalarial properties (Andersen et al., 1995; Noedl et al., 2001,
007; Yeo and Rieckmann, 1995) and could be used in association
ith rectal artesunate, an antimalarial drug recommended in “non-
er-os” children with malaria (Gomes et al., 2009; WHO, 2010).
he advantage of adding AZ would be threefold: mutual protection
gainst malaria parasite resistance; potentially increased activity
n malaria; extension of treatment to non-malaria, bacterial infec-
ions (acute respiratory infections, sepsis, meningitis) which are
urrently not covered and are very difﬁcult to distinguish from
alaria (Berkley et al., 2005a,b).
Advancements made in the development of this product with
ublic funds will curtail time and costs of industrial development,
hus making the drug affordable.
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